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ABSTRACT
Objective: The study’s main goal has been to identify scientific evidence on the management of anorexia in 
palliative care. Methods: This is an integrative review, whose data collection occurred by researching four 
databases/virtual libraries. Articles in Portuguese, English, and Spanish, published over the last ten years 
and with the full text available, were included. Results: 25 articles were selected, and two thematic axes 
were assigned to better illustrate the data found: pharmacological and non-pharmacological management. 
Corticosteroids, progestins, anamorelin, and dronabinol were the most-researched drugs for the control of 
anorexia, with greater evidence of effectiveness for the first three. In the non-pharmacological treatment, 
nutritional counseling was the most recommended measure, including the fortification of foods and the use of 
supplements and the more-controversial artificial nutrition. Conclusion: The findings of this review may aid 
in the development of protocols for the treatment of anorexia in palliative care.
Descriptors: Palliative care, Nutrition, Diet therapy, Anorexia, Drug therapy.
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RESUMO
Objetivo: Identificar evidências científicas acerca das condutas para o manejo 
da anorexia em cuidados paliativos. Métodos: Trata-se de uma revisão 
integrativa, cujo levantamento bibliográfico dos dados deu-se através da 
pesquisa em quatro bases de dados/bibliotecas virtuais. Incluíram-se artigos 
em português, inglês e espanhol, publicados nos últimos dez anos e com o 
texto completo disponível. Resultados: Foram elegíveis 25 artigos, e foram 
atribuídos dois eixos temáticos para melhor ilustrar os dados encontrados: o 
manejo farmacológico e o não-farmacológico. Corticosteroides, progestinas, 
anamorelina e dronabinol foram os fármacos mais pesquisados para o 
controle da anorexia, com maiores evidências de eficácia nos 3 primeiros. 
No contexto não-farmacológico, o aconselhamento nutricional foi a medida 
mais indicada, incluindo a fortificação de alimentos e uso de suplementos e 
a nutrição artificial mais controversa. Conclusão: Os achados desta revisão 
podem colaborar para a elaboração de protocolos para o manejo da anorexia 
em cuidados paliativos.
Descritores: Cuidados paliativos, Nutrição, Dietoterapia, Anorexia, 
Tratamento farmacológico.
RESUMEN
Objetivo: El propósito principal del estudio ha sido identificar evidencia 
científica sobre el manejo de la anorexia en los cuidados paliativos. Métodos: 
Esta es una revisión integradora, cuya investigación bibliográfica de datos 
ocurrió mediante búsqueda en cuatro bases de datos/bibliotecas virtuales. Se 
incluyeron artículos en portugués, inglés y español, publicados en los últimos 
diez años y con texto completo disponible. Resultados: Fueron elegibles 25 
artículos, siendo atribuidos dos ejes temáticos para ilustrar mejor los datos 
encontrados: el manejo farmacológico y el no farmacológico. Corticosteroides, 
progestinas, anamorelina y dronabinol han sido los fármacos más buscados 
para el control de la anorexia, con mayores evidencias de eficacia en los 3 
primeros. En el contexto no farmacológico, el asesoramiento nutricional 
fue la medida más indicada, incluyendo la fortificación de alimentos y uso 
de suplementos y la nutrición artificial más controversia. Conclusión: Los 
hallados de esta revisión pueden colaborar para la elaboración de protocolos 
para el manejo de la anorexia en cuidados paliativos.
Descriptores: Cuidados paliativos, Nutrición, Dietoterapia, Anorexia, 
rTatamiento farmacológico. 
INTRODUCTION
Historically, the philosophy of Palliative Care (PC) 
is seen in the early Christian era. In Brazil, its beginning 
dates from the 1980s, with potential growth from the 
year 2000.1 The World Health Organization (WHO) 
conceptualizes Palliative Care as an approach that seeks to 
prevent and alleviate suffering, thus improving the quality 
of life of patients and family members who are affected by 
fatal diseases, through early identification, evaluation and 
treatment of pain and other physical, psychosocial, and 
spiritual symptoms.2 
Anorexia is the loss of appetite or the desire to eat, 
being common among patients with serious, chronic, and 
life-threatening diseases.3 In cases of advanced diseases, it 
can lead to a decline in nutritional status, loss of lean body 
mass, as well as impaired muscle function, a fact that affects 
the quality of life and are indicators of poor prognosis.4
From this perspective, the role of the nutritionist is seen 
as a major challenge in clinical practice in dealing with 
patients in palliative care, especially in the management 
of common clinical symptoms such as anorexia, weight 
loss and others that have a direct impact on the nutritional 
condition, with the need of an intervention that seeks to 
maintain nutritional status as well as promote well-being 
in the various stages of the disease. The objectives of 
nutritional support, as the end of life approaches, focus 
more on the quality of life than on nutritional adequacy. 
This is where the great dilemma between reconciling 
nutritional intervention and the purpose of palliation is to 
offer comfort and help control symptoms.5
Considering the aforesaid, the following guiding 
problem arises: What are the most effective conducts in the 
management of anorexia in palliative care?
Because of the problem raised, this study aims to 
identify scientific evidence about the management of 
anorexia in palliative care.  
METHODS
It is an integrative review whose methodological path 
was divided into six stages: identification of the theme 
and selection of the guiding question, establishment of 
inclusion and exclusion criteria and search in the literature, 
categorization of studies, evaluation of included studies, 
interpretation of results and presentation of the review.6
The bibliographic survey was carried out through 
electronic search in the following databases: Medical 
Literature Analysis and Retrieval System Online 
(MEDLINE)/PubMed and Literatura Latino-Americana e 
do Caribe em Ciências da Saúde (LILACS) [Latin American 
and Caribbean Literature in Health Sciences], available 
at the Virtual Health Library (VHL) and at the electronic 
library Scientific Electronic Library Online (SciELO) 
from March to May 2019 using the following controlled 
descriptors, based on Health Sciences Descriptors (DeCS): 
“palliative care”, “nutrition” and “anorexia” together with 
the Boolean operator “AND”, the term “nutrition” being 
replaced by the descriptor “diet therapy” using the Boolean 
operator “OR”.
The inclusion criteria were complete articles published 
in the last ten years, in Portuguese, English, and Spanish, 
which presented the theme proposed in the title, abstract 
or descriptors. Exclusion criteria were: letters to the editor; 
editorials, and articles that were duplicated.
After selecting the articles, the relevant information for 
each study was defined, describing them in tables, grouping 
them into thematic categories and interpreting them in the 
light of the literature.
   
RESULTS AND DISCUSSION
After identifying and selecting publications as presented 
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in the PRISMA flowchart (Figure 1), 25 articles were 
analyzed, whose inclusion criteria were met and answered 
the guiding question, as shown in Table 1 and 2.
Figure 1 – Flowchart for identification and selection of publications according 
to the PRISMA Statement.7
Table 1 – Identification of the articles included in the integrative review. 
João Pessoa City, Paraíba State, Brazil, 2019
Table 2 - Main results of the articles included in the review. João Pessoa 
City, Paraíba State, Brazil, 2019
ONS: Oral Nutritional Support; PN: Parenteral Nutrition; NT: Nutritio-
nal therapies; OLZ: Olanzipine; DC: Dietary Counseling; MA: Megestrol 
acetate; QOL: Quality of Life; PC: Palliative Care; AN: Artificial Nutrition; 
NS: Nutritional Status.
It is observed that 64% of the articles bring the 
management of anorexia in the context of the cancer 
patient. This brings the perspective of the large number of 
publications on PC related to cancer patients, given that 
this pathology is the second leading cause of death in the 
world, where late presentation and inaccessible diagnosis 
and treatment are common31 being the palliative approach 
essential.
To better illustrate the results, two thematic axes were 
elaborated regarding the management of anorexia in PC: 
pharmacological and non-pharmacological.
PHARMACOLOGICAL MANAGEMENT
From a total of 25 articles, 24 (96%) address the use of 
drugs used in the management of anorexia in PC. The most 
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cited medications were corticosteroids (70.8%), progestins 
(62.5%), anamorelin (33.3%), and dronabinol (33.3%).
Corticosteroids
The use of corticosteroids has demonstrated beneficial 
evidence in cancer patients, including dexamethasone, 
methylprednisolone, and betamethasone.23 According to 
the European Society of Parenteral and Enteral Nutrition 
(ESPEN) Guideline for cancer patients,17 there is insufficient 
evidence to recommend a particular type of corticosteroids 
over another, however, dexamethasone is often selected due 
to the absence of mineralocorticoid effects.28
In 2017, Matsuo et al conducted in Japan that aimed 
to identify the potential factors that predict responses to 
corticosteroids for anorexia in cancer patients receiving PC 
services and to explore the clinical effects of this treatment. 
Patients had advanced cancer and an anorexia intensity 
score above 4 on a scale of 0 to 10 (NRS). It was identified 
that the most important predictor was the patient’s general 
condition (Palliative Performance Scale - PPS> 40) and 
corticosteroids achieved a 2.3-point reduction on the NRS 
anorexia scale. It was concluded that patients with advanced 
cancer can benefit from the use of corticosteroids if they 
have a reasonable general condition and are not drowsy.19
The anti-anorectic effect of corticosteroids is considered 
transitory, disappearing after a few weeks. The most 
common side effects are associated with the duration of 
the treatment and cumulative dose: Cushing’s syndrome, 
insulin resistance, hyperglycemia, adrenal insufficiency, 
immunosuppression, risk of infection, and osteopenia.14,17 
ESPEN (2017) suggests that the use of corticosteroids in 
cancer patients should be indicated in cases of short life 
expectancy, especially if they have other symptoms that can 
also be relieved with this type of medication, such as pain 
or nausea, due to adverse effects with prolonged use.17
Progestins (Megestrol Acetate)
Among the most studied progestational agents, is 
Megestrol Acetate (MA) - a synthetic derivative of the 
hormone progesterone.28 Recent reviews point to MA as 
an effective appetite stimulant, being considered a first-line 
treatment for anorexia in cancer patients.29 A review 
published in The Cochrane Library in 2013 showed that 
MA improves appetite, has a small effect on weight gain, 
does not improve the Quality of Life (QOL) and can have 
side effects, especially when used in high doses, such as the 
occurrence of thrombi and deaths.27 Corroborating these 
findings, Childs and Jatoi presented, in 2019, a review of 
anorexia and how to manage it in cancer patients, the result 
of which showed that MA improves appetite in patients with 
advanced cancer.4 The most common side effects common 
uses of MA were: increased risk of thromboembolism; 
being increased by concomitant chemotherapy;28 diarrhea; 
adrenal insufficiency,14 and dyspnea.12
ESPEN Guideline brings, as a consensus, considering 
the use of MA to increase the appetite of cancer patients 
in advanced conditions, being aware of the serious side 
effects. With a high level of evidence, there is an increase in 
appetite and weight, but no increase in lean mass.17
The duration of the response to MA is longer than with 
corticosteroids, which is indicated in patients with a life 
expectancy of a few months or more. For patients with low 
life expectancy or a history of thromboembolism, the use 
of dexamethasone is indicated, as it is less likely to promote 
side effects of corticosteroids in the short term.28 From all 
the articles studied, the common doses of MA use were 
from 160 to 1,600mg, with a risk of thromboembolism and 
other adverse events at doses above 800mg.11, 17, 22, 24-26, 28 
Anamorelin
Anamorelin is analogous to ghrelin, but with a half-
life of almost 7 to 12 hours, therefore, longer than natural 
ghrelin,16 and it has been tested as an appetite-stimulating 
agent, demonstrating its ability to improve anorexia in PC.4
Prommer, in 2017, carried out an oncological update 
that aimed to analyze the effect of anamorelin on cachexia, 
concluding that the drug reverses the symptoms of anorexia 
and increases lean mass in patients with advanced lung 
cancer, representing a new option for the management of 
cancer anorexia-cachexia.16
The dosage used for anamorelin in the studies was 
100 mg/day and the common adverse reactions were 
hyperglycemia, nausea and edema.12
Dronabinol
Dronabinol is the most studied synthetic cannabinoid 
to reverse anorexia in PC patients.22
ESPEN Guideline shows that although dronabinol 
can improve chemosensory perception and appetite in 
patients with anorexia, such evidence is weak and does not 
support a recommendation.17 In contrast, a study carried 
out in Canada, with 54 patients undergoing cannabinoid 
treatment for 3 months to assess changes in appetite scores, 
it showed, as a result, a significant improvement in this 
score between onset and follow-up after treatment, with no 
significant difference in weight.12
A recent systematic review assessed the use of 
cannabinoids in PC, so the authors concluded that no 
recommendation can be made for the use of cannabinoids 
in the PC treatment of cancer, HIV/AIDS (Human 
Immunodeficiency Virus/Acquired Immunodeficiency 
Syndrome) or dementia, and further research is needed to 
identify safety and effectiveness of this drug.13 Studies that 
compared MA with dronabinol concluded that it is inferior 
for improving appetite and weight gain, in addition to not 
adding any benefit when used in combination with MA.22,4
A recent systematic review assessed the use of 
cannabinoids in PC, so the authors concluded that no 
recommendation can be made for the use of cannabinoids 
in the PC treatment of cancer, HIV/AIDS or dementia, 
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and further research is needed to identify safety and 
effectiveness of this drug. Studies comparing MA with 
dronabinol concluded that it is inferior for improving 
appetite and weight gain, and does not add any benefit 
when used in combination with MA. 
The main adverse effects of cannabinoids are drowsiness, 
dizziness, euphoria,14 cognitive deceleration,24 anxiety, 
fatigue, dry mouth,12 hallucinations, and cardiovascular 
disorders, requiring a careful prescription because it is a 
drug listed as psychotropic and narcotic.17
NON-PHARMACOLOGICAL MANAGEMENT
The non-pharmacological management of anorexia is 
addressed in 40% of the articles, occurring mainly through 
Nutritional Counseling (NC), Oral Supplementation (OS) 
and Artificial Nutrition (AN).
Food plays an important role in the biopsychosocial 
well-being of patients in PC, affecting their QOL. In 
general, NC is the first intervention in anorectic patients 
in PC and occurs after the evaluation by the nutritionist, 
verifying food intake and the presence of symptoms related 
to low consumption, prescribing diet therapy individually.17 
Counseling interventions provide instructions 
regarding food fortification, changes in consistency, 
guidance on the frequency and quantity of meals, taking 
into account the clinical picture and related symptoms, 
in addition to the conducive environment and family 
support, given that good communication it is essential to 
achieve the greater success of the intervention.4,5,15,29,17,18 It 
is important to remember that, in PC, the objectives of diet 
therapy should be reviewed in the light of the stage of the 
underlying disease, recognizing, as the greatest intention, 
the search for comfort, relief of unpleasant symptoms and 
promotion of better QOL.5
In 2009, Andrew et al. sought to determine whether 
standardized assessment and management of common 
symptoms improved the symptoms of cancer patients in 
PC. The most widely used non-pharmacological advice 
was: eat little and often, eat what you want, when you want, 
use small dishes and eat your favorite foods. Symptoms 
improved over 4 weeks of the study, suggesting that basic 
advice and simple medication measures can have a rapid 
impact on symptoms.30 
Day, in 2017, brought some strategies for managing 
anorexia listed by Miller in 2014: small meals or frequent 
snacks, snacks like nuts, seeds and dried fruits, individual 
desserts and enjoying the days with a better appetite. As 
for food fortification, the strategy would be to reduce the 
portions and increase the caloric-protein density by adding 
2 to 4 tablespoons of skimmed milk powder in 580 mL 
of whole milk, using this preparation in cereals, soups, 
puddings, and vitamins. Another method is to add cheeses, 
butter, and creams to soups and potatoes and to add lentils 
or beans to soups. For those who have early satiety and are 
unable to eat a complete meal, adding protein to snacks 
through individual desserts, Greek type yogurt, seeds, 
avocado, and cheese is valid.5
Corroborating Day’s review (2017), Lowey (2017) 
brought, as a non-pharmacological intervention: mouth 
care; encouraging small meals and frequent snacks; a larger 
meal in the morning or, when energy is better, start meals 
with fortified foods or liquids; avoid foods and liquids 
with little or no nutritional value; provide cultural dishes 
and maintain the rituals of family meals, with a pleasant 
environment.15 In addition to these interventions, Hurlow 
(2019) brought the concern with food support to ensure 
accessibility to food and drinks through a better table 
positioning, use of implements adapted and physical 
assistance for food.9
Regarding the impact on weight gain, response to 
treatment and survival, the studies by Von Gunten and 
Gafford (2013), Hagmann and collaborators (2018), and 
Childs and Jatoi (2019) show that there is no positive 
impact in this sense, however, nutritional intervention is 
encouraged, in the last two articles cited, by the observation 
that many patients receiving NC report greater health and 
general well-being benefits than those who do not, thus 
justifying the importance of including the nutritionist as 
part of the PC team, showing interest and commitment to 
the well-being of those who have difficulties in eating.28, 14, 4
The use of Oral Nutritional Support (ONS) is indicated 
when an enriched diet is ineffective to meet needs and 
when there is low acceptance due to fluid retention and 
ascites.18, 26 The prescription must be individualized and its 
use reevaluated.5 
A study points to a reflection regarding the use of 
ONS in cancer patients with no appetite, whose strategy 
is related to the attempt to reduce weight loss. The use of 
ONS does not treat anorexia itself and acceptance of the 
supplement is hampered by inappetence. In this sense, 
there is the suggestion of trying to minimize anorexia to 
treat weight loss.4
The use of enteral and parenteral nutritional support 
in PC is quite controversial. Childs and Jatoi (2019) bring 
ESPEN’s uncertainty regarding the use of Enteral Nutrition 
(EN) in cancer patients, supporting its use only in patients 
with no food intake for more than a week or less than 60% of 
the needs for more than 1-2 weeks, with escalation between 
ONS, followed by EN and, only lastly, Parenteral Nutrition 
(PN).18 The National Comprehensive Cancer Network 
guidelines for PC advise to consider EN or PN only when 
the prognosis is longer than weeks to days, however, this 
decision must be well determined individually, and in most 
cases, in patients with advanced cancer, there is a strong 
discouragement regarding the use of invasive nutritional 
support.4
In line with these findings, Day (2017) suggests that AN 
should be a patient-focused approach, taking into account 
their QOL, functional status and the path of the disease. 
As death approaches, it is natural for there is a reduction 
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in oral intake and continued AN can contribute to the 
exacerbation of symptoms, such as dyspnea, causing greater 
discomfort. The interruption of AN should be well worked 
out with family members, since many see this attitude as 
hastening death by starvation, when, in fact, the intention 
is to minimize suffering.5
Several studies such as those by Von Gunten and 
Gafford (2013), Goto (2019), Kumar and Panda (2014), 
and Lowey (2017) concluded that the use of AN does 
not, by itself, reverse anorexia and can worsen the QOL 
of patients, mainly in the terminal stage, due to the 
occurrence of complications such as nausea and vomiting, 
diarrhea, aspiration, dyspnea, edema, increased incidence 
of infections, and mechanical complications.28,8,26,15  
CONCLUSIONS
The present review identified that the management of 
anorexia in PC must be done individually, according to the 
symptoms presented, disease stage and nutritional conditions. 
The use of dexamethasone is more indicated in patients 
with low life expectancy due to the potential side effects in 
cumulative doses, whereas MA is recommended for patients 
with a longer life expectancy, and should be avoided when 
there is a history of thrombotic events. 
It was shown that anamorelin reverses anorexia in patients 
with lung cancer, and that the use of dronabinol did not 
show better effects on anorexia compared to the other drugs 
studied. AN is the main non-pharmacological measure, see-
king to promote the relief of symptoms related to low food 
intake, in addition to guidelines for the use of fortified foods, 
stimulation of cultural meals and family support regarding 
accessibility and physical assistance. For the use of enteral and 
parenteral support, one must take into account the prognosis 
and the occurrence of complications.
These findings can assist nutritionists in the development 
of protocols for the treatment of this symptom so frequent 
in the context of PC, in order to promote a better QOL and 
well-being for these patients.
It is observed that most of the studies included in the 
research are review articles, given the low number of original 
publications bringing the theme addressed, which would 
be a limitation of this study, highlighting the need for more 
research related to the management of anorexia in patients 
in palliative care.     
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